Cipla Ltd. — Capital/Financing Update 2025

Dec 19, 2025

==> picture [84 x 30] intentionally omitted <==

19[th] December, 2025

(1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA EQ

• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG

Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Exclusive Supply and Marketing Agreement for Pfizer’s brands

Pursuant to Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that Cipla Limited (‘Company’) has entered into an exclusive Supply and Marketing Agreement with Pfizer Products India Private Limited and Pfizer Limited (hereinafter together referred as “Pfizer”) for marketing and distribution of four brands of Pfizer, viz., Corex, Dolonex, Neksium and Dalacin C for a period of 5 years.

The additional details required to be disclosed, pursuant to the Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as Annexure A.

A joint press release issued by Pfizer and Cipla in this regard in enclosed herewith as Annexure B.

This intimation is being made to the stock exchanges as part of our commitment to good corporate governance practices.

We request you to kindly take the same on record.

Yours faithfully,

For Cipla Limited

RAJENDRA Digitally signed by RAJENDRA CHOPRA CHOPRA Date: 2025.12.19 11:22:52 +05'30' Rajendra Chopra

Company Secretary Prepared by: Chirag Hotchandani

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Numbe r L24239MH1935PLC002380

==> picture [84 x 30] intentionally omitted <==

Annexure - A

Details as per the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11[th] November, 2024

Sr. No.	Particulars	Details
1	Name of the entity with which agreement is signed	Pfizer Products India Private Limited and Pfizer Limited (hereinafter together referred as “Pfizer”)
2	Area of agreement	The agreement is signed for a period of 5 (five) years within the territory of India. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C*. Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.
3	Scope of business operation
4	Significant terms and conditions of agreement
5	Domestic / International	Domestic
6	Share exchange ratio/JV Ratio	Not applicable
7	Details of consideration paid /received in agreement	No upfront consideration paid/received as part of the agreement. Other Commercial terms, as agreed between the parties.
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired. If yes, nature of interest and details thereof and whether the same is done at arm’s length.	Not applicable
9	Size of the entity	Not applicable
10	Rationale and benefit expected	The Company has an extensive customer understanding, distribution reach and network. The Company believes that with the said Supply and Marketing Agreement would ensure a wider reach and depth across India for the said medicines.

*Dalacin C is a part of Pfizer Products India Pvt. Ltd; Corex Dx; Corex LS, Dolonex and Neksium are a part of Pfizer Ltd.

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Numbe r L24239MH1935PLC002380

Annexure B

==> picture [57 x 21] intentionally omitted <==

==> picture [77 x 37] intentionally omitted <==

Pfizer & Cipla Announce Exclusive Marketing and Distribution Partnership for Select Brands in India

• This partnership will significantly enhance availability of key brands for patients across the country

Mumbai, December 19, 2025: Pfizer India and Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced a partnership where Cipla will exclusively market and distribute four brands of Pfizer in India.

Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India. Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.

Meenakshi Nevatia, Country President, Pfizer India, said, “At Pfizer, expanding the reach of our medicines for patients is paramount and we are delighted to partner with Cipla to achieve this common mission. With Pfizer’s legacy of breakthroughs, quality and innovation, and Cipla’s extensive distribution reach and network, we believe this partnership will help meet the needs of millions of patients across India effectively. Together, we are committed to advancing healthcare outcomes and enhancing patient lives everywhere.”

Achin Gupta, Global Chief Operating Officer, Cipla Ltd. said, “At Cipla, we believe meaningful partnerships help make strong brands even stronger. This association with Pfizer aligns with our continued focus on building a formidable presence across key therapy areas and enhancing access to high quality treatments guided by our purpose of ‘Caring for Life’. Our distribution capabilities will support wider reach for such trusted therapies to patients who need them the most.”

Pfizer has been serving patients across India for over 75 years, driven by a commitment to deliver breakthroughs that transform lives. This marks the first partnership between Pfizer and Cipla in India. The agreement aims to make Pfizer’s medicines widely available by combining its well-established portfolio with Cipla’s deep market reach.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply cutting-edge science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at h�p://www.pfzer.co.in

==> picture [57 x 21] intentionally omitted <==

==> picture [77 x 37] intentionally omitted <==

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep’25), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT Aug’25), and 4th largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Aug’25). For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deeprooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For media inquiries:

Uma Balakrishnan Corporate Communications M: 82913 12162 Heena Kanal E: uma.balakrishnan@pfizer.com E-Mail: CorpComm@cipla.com

Investor Relations Diksha Maheshwari E-Mail: Investor.Relations@cipla.com